3 news items
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
HRTX
29 May 24
® (bupivacaine and meloxicam) extended-release solution Vial Access Needle ("VAN
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
HRTX
24 Apr 24
.
The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator
Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
HRTX
12 Mar 24
The ZYNRELEF Vial Access Needle ("VAN") program, to allow for the rapid preparation and administration of ZYNRELEF
- Prev
- 1
- Next